Tag: heart failure

Advances in Left Bundle Branch Pacing: Definition, Evaluation, and Applications

Announcing a new article publication for Cardiovascular Innovations and Applications journal.     Left bundle branch pacing (LBBP) emerged as a new physiological pacing strategy during the past several years. Recent observational studies have demonstrated the advantages of LBBP, including a high success rate, stable pacing parameters, and excellent clinical benefits. Widespread adoption of LBBP will depend on improvements in device/lead technology and further verification of its efficacy in large randomized clinical trials.

This article summarizes recent advancements in LBBP, including the definition and evaluation of left bundle branch capture, LBBP applications, and future directions in this growing field.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0047

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Jiaxing Zeng, Siyuan Xue and Fengwei Zou et al. Advances in Left Bundle Branch Pacing: Definition, Evaluation, and Applications. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0047

Loading

Cost Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors Compared with Mineralocorticoid Receptor Antagonists among Patients with Heart Failure and a Reduced Ejection Fraction

Announcing a new article publication for Cardiovascular Innovations and Applications journal.    Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are approved for heart failure with reduced ejection fraction (HFrEF). However, their cost-effectiveness remains unknown. The authors of this article compare the cost-effectiveness of SGLT2i versus mineralocorticoid antagonists (MRAs).

Data from the RALES, EPHESUS, EMPHASIS, DAPA-HF, and EMPEROR-Reduced trials were included. We calculated the risk-ratio (RR) for a composite of cardiovascular death or heart failure hospitalization (CV death-HHF), all-cause mortality, and heart failure hospitalization (HHF) between MRAs and SGLT2i. A Markov model was developed to simulate the progression of HFrEF over 5 years. The primary outcome was incremental cost-effectiveness ratio (ICER), measured by cost per quality-adjusted life-year (QALY) gained.

The authors observed a similar benefit in CV death-HHF (RR 1.04; 95% CI 0.82–1.31), all-cause mortality (RR 0.91; 95% CI 0.78–1.06), and HHF (RR 1.05; 95% CI 0.84–1.31) between MRAs and SGLT2i. In a 5-year model, no difference in survival was observed between treatments. MRAs were associated with lower cost ($63,135.52 vs. $80,365.31) and more QALYs gained per patient (2.53 versus 2.49) than SGLT2i. The ICER for SGLT2i versus MRAs was $-172,014.25/QALY, in favor of MRAs.

MRAs and SGLT2i provided similar benefits; however, MRAs were a more cost-effective treatment than SGLT2i.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0037

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Jingchaun Guo, Matthew R. Petersen and Huilin Tang et al. Cost Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors Compared with Mineralocorticoid Receptor Antagonists among Patients with Heart Failure and a Reduced Ejection Fraction. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0037

Loading

Mechanisms of Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure

Announcing a new article publication for Cardiovascular Innovations and Applications journal.    Heart failure is an end stage cardiac disease that has been associated with high mortality and rehospitalization rates in previous decades, in spite of standard anti-heart failure therapy, thus posing a major social and economic burden on public health.

Several studies have demonstrated that sodium-glucose cotransporter 2 inhibitors (SGLT2i), anti-hyperglycemic drugs whose function is independent of islet function, have significant positive effects on prognosis and quality of life, by decreasing mortality and readmission rates in patients with heart failure.

To increase general clinicians’ understanding and facilitate the practical application of SGLT2i in the treatment of heart failure, the mechanisms through which SGLT2i alleviate heart failure are reviewed in this article.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0028

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Jiangjun Wei and Jianlin Du. Mechanisms of Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0028

Loading

Call for Papers

You are invited to submit an article to Cardiovascular Innovations and Applications (CVIA).

Cardiovascular Innovations and Applications (CVIA) seeks to publish focused articles and original clinical research that explore novel developments in cardiovascular disease, effective control and rehabilitation in cardiovascular disease, and promote cardiovascular innovations and applications for the betterment of public health globally. The journal publishes basic research that has clinical applicability to promote timely communication of the latest insights relating to coronary artery disease, heart failure, hypertension, cardiac arrhythmia, prevention of cardiovascular disease with a heavy emphasis on risk factor modification.

CVIA was launched in 2015 as an open access journal, offering high visibility and discoverability through its open access publishing approach. As part of its mandate to help bring interesting work and knowledge from around the world to a wider audience, CVIA will actively support authors through open access publishing and through waiving author fees.  

The journal welcomes the following article types:

  • Editorials
  • Original Research
  • Review Articles
  • Commentaries
  • Case Reports
  • Case Studies
  • Methodology papers related to clinical trials
  • Letters to the Editor

For more information on our journal please see the CVIA website https://cvia-journal.org/; recently published content is available on ScienceOpen  https://www.scienceopen.com/search#collection/32b77252-732d-468f-a6f9-9637d4762967 .

Submissions to Cardiovascular Innovations and Applications (CVIA) can be made using ScholarOne, the online submission and peer review system. Registration and access is available at https://mc04.manuscriptcentral.com/cvia-journal. There are no author submission or article processing fees.

CVIA is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ and Index Copernicus Databases.

Follow CVIA on Twitter @CVIA_Journal; or Facebook https://www.facebook.com/cvia.journal/.

Articles of interest include:

Psychosocial Risk Factors and Cardiovascular Disease: Epidemiology, Screening, and Treatment Considerations

Novel SPECT Technologies and Approaches in Cardiac Imaging

Global Burden of Cardiovascular Disease

Clinical Characteristics and Durations of Hospitalized Patients with COVID-19 in Beijing: A Retrospective Cohort Study

Rationale and Design of the Randomized Controlled Trial of Intensive Versus Usual ECG Screening for Atrial Fibrillation in Elderly Chinese by an Automated ECG System in Community Health Centers in Shanghai (AF-CATCH)

The Effect of Home-Based Cardiac Rehabilitation on Functional Capacity, Behavior, and Risk Factors in Patients with Acute Coronary Syndrome in China

Current Management Strategies in Patients with Heart Failure and Atrial Fibrillation: A Review of the Literature

Telemedicine: Its Importance in Cardiology Practice. Experience in Chile

Management of Hypertension: JNC 8 and Beyond

The Relationship Between Mean Platelet Volume and In-Hospital Mortality in Geriatric Patients with ST Segment Elevation Myocardial Infarction Who Underwent Primary Percutaneous Coronary Intervention

Loading

CVIA has just published the first issue of Volume 6

Highlighted papers in the issue are as follows:

Efficacy and Renal Tolerability of Ultrafiltration in Acute Decompensated Heart Failure: A Meta-analysis and Systematic Review of 19 Randomized Controlled Trials

 By Yajie Liu and Xin Yuan (DOI 10.15212/CVIA.2021.0020).

In this important Review paper, the authors discuss, the importance of acute decompensated heart failure (ADHF)  which is a life-threatening and costly disease. Controversy remains regarding the efficacy and renal tolerability of ultrafiltration for treating ADHF.  The authors performed a meta-analysis to evaluate this clinical issue. A search of PubMed, EMBASE, and the Cochrane database of controlled trials was performed from inception to March 2021 for relevant randomized controlled trials. The quality of the included trials and outcomes was evaluated with the use of the risk of bias assessment tool and the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach, respectively. The risk ratio and the standardized mean difference (SMD) or weighted mean difference (WMD) were computed and pooled with fixed-effects or random-effects models. Results: This meta-analysis included 19 studies involving 1281 patients. Ultrafiltration was superior to the control treatments for weight loss (WMD 1.24 kg, 95% confidence interval [CI] 0.38–2.09 kg, P = 0.004) and fluid removal (WMD 1.55 L, 95% CI 0.51–2.59 l, P = 0.003) and was associated with a significant increase in serum creatinine level compared with the control treatments (SMD 0.15 mg/dL, 95% CI 0.00–0.30 mg/dL, P = 0.04). However, no significant effects were found for serum N-terminal prohormone of brain natriuretic peptide level, length of hospital stay, all-cause mortality, or all-cause rehospitalization in the ultrafiltration group. Conclusions: The use of ultrafiltration in patients with ADHF is superior to the use of the control treatments for weight loss and fluid removal but has adverse renal effects and lacks significant effects on long-term prognosis, indicating that this approach to decongestion in ADHF patients is efficient for fluid management but less safe renally.

Clinical Characteristics and Durations of Hospitalized Patients with COVID-19 in Beijing: A Retrospective Cohort Study

By Wen Zhao, Xiangyi Zha, Ning Wang, Dongzeng Li, Aixin Li and Shikai Yu (DOI 10.15212/CVIA.2021.0019)

In this important research paper, the authors provide information on clinical characteristics and different durations of COVID-19 and identify the potential risk factors for longer hospitalization of patients with COVID-19. In this retrospective study, the researchers enrolled 77 patients (age 52 ± 20 years; 44.2% males) with laboratory confirmed COVID-19 admitted to Beijing YouAn Hospital between January 21 and February 8, 2020. Epidemiological, clinical, and radiological data on admission were collected; complications and outcomes were followed up until February 26, 2020. The end point of the study was discharge alive within 2 weeks. Cox proportional-hazards regression was performed to identify risk factors for longer hospitalization. Results: Of 77 patients, there were 34 males (44.2%), 24 (31.2%) with comorbidities, 22 (28.6%) with lymphopenia, 20 (26.0%) with severe COVID-19, and 28 (36.4%) with complications. By the end of follow-up, 64 patients (83.1%) were discharged home, eight remained in hospital, and five had died. Thirty-six patients (46.8%) were discharged within 14 days and thus reached the study end point, including 34 of the 57 patients with nonsevere COVID-19 (59.6%) and two of the 20 patients with severe COVID-19 (10%). The overall cumulative probability of the end point was 48.3%. Hospital length of stay and the duration from exposure to discharge for the 64 discharged patients were 13 (10–16.5) days and 23 (18–24.5) days, respectively. A multivariable stepwise Cox regression model showed that bilateral pneumonia on CT scan, shorter time from illness onset to admission, severity of disease, and lymphopenia were independently associated with longer hospitalization. Conclusions: COVID-19 has a shorter duration of disease and hospital length of stay than severe acute respiratory syndrome. Bilateral pneumonia on CT scan, shorter period from illness onset to admission, lymphopenia, and severity of disease are the risk factors for longer hospitalization of patients with COVID-19.

CTO (Chronic Total Occlusion)

By Charles Richard Conti and Calvin Choi (DOI 10.15212/CVIA.2021.0015)

In this important Commentary paper,  the authors consider the problem of CTO. There are no studies in patients with non-viable myocardium subtending a CTO to show improvement of regional wall motion after opening of the CTO. Patients without symptomatic multivessel CAD or no symptoms of angina have not been evaluated since there was no indication for study in the catheterization laboratory. CTO of collateral vessels that feed viable myocardium may lead to improvement in regional

myocardial wall motion and thus potentially a decrease in mortality. CTO recanalization in patients with active angina improve symptoms despite limited ability to demonstrate an improvement in wall motion.

Loading